Receptor Tyrosine Kinases and Inhibitors in Lung Cancer

Lung cancer is a deadly disease with high mortality and morbidity. Most cases of lung cancer are due to non-small cell carcinoma, with 16% of cases being small cell carcinoma. The biology at a cellular level is of interest at many levels. Knowing cellular pathways helps to further enhance our knowle...

Full description

Saved in:
Bibliographic Details
Main Authors: Evan Pisick, Simha Jagadeesh, Ravi Salgia
Format: Article
Language:English
Published: Wiley 2004-01-01
Series:The Scientific World Journal
Online Access:http://dx.doi.org/10.1100/tsw.2004.117
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832551887675588608
author Evan Pisick
Simha Jagadeesh
Ravi Salgia
author_facet Evan Pisick
Simha Jagadeesh
Ravi Salgia
author_sort Evan Pisick
collection DOAJ
description Lung cancer is a deadly disease with high mortality and morbidity. Most cases of lung cancer are due to non-small cell carcinoma, with 16% of cases being small cell carcinoma. The biology at a cellular level is of interest at many levels. Knowing cellular pathways helps to further enhance our knowledge of how lung cancer cells survive, proliferate, and metastasize. The receptor tyrosine kinases (RTKs) located at the cellular membrane are becoming of great interest as sites for targeted therapies for lung cancers. This review will discuss the RTKs that are involved in lung cancers and the newer therapies that are being tested. We will specifically discuss receptors such as epidermal growth factor receptor, c-Kit receptor, VEGF receptor, c-Met receptor, insulin growth factor receptor, and Eph receptor. The inhibitors against the specific RTKs are in various preclinical and clinical trials, and this will be detailed.
format Article
id doaj-art-7e184039e6a747909c08f5d59c44731c
institution Kabale University
issn 1537-744X
language English
publishDate 2004-01-01
publisher Wiley
record_format Article
series The Scientific World Journal
spelling doaj-art-7e184039e6a747909c08f5d59c44731c2025-02-03T06:00:07ZengWileyThe Scientific World Journal1537-744X2004-01-01458960410.1100/tsw.2004.117Receptor Tyrosine Kinases and Inhibitors in Lung CancerEvan Pisick0Simha Jagadeesh1Ravi Salgia2Tufts-New England Medical Center, Tufts University School of Medicine, Boston MA, USAUniversity of Chicago, Section of Hematology and Oncology, Pritzker Medical School, Chicago, IL, USAUniversity of Chicago, Section of Hematology and Oncology, Pritzker Medical School, Chicago, IL, USALung cancer is a deadly disease with high mortality and morbidity. Most cases of lung cancer are due to non-small cell carcinoma, with 16% of cases being small cell carcinoma. The biology at a cellular level is of interest at many levels. Knowing cellular pathways helps to further enhance our knowledge of how lung cancer cells survive, proliferate, and metastasize. The receptor tyrosine kinases (RTKs) located at the cellular membrane are becoming of great interest as sites for targeted therapies for lung cancers. This review will discuss the RTKs that are involved in lung cancers and the newer therapies that are being tested. We will specifically discuss receptors such as epidermal growth factor receptor, c-Kit receptor, VEGF receptor, c-Met receptor, insulin growth factor receptor, and Eph receptor. The inhibitors against the specific RTKs are in various preclinical and clinical trials, and this will be detailed.http://dx.doi.org/10.1100/tsw.2004.117
spellingShingle Evan Pisick
Simha Jagadeesh
Ravi Salgia
Receptor Tyrosine Kinases and Inhibitors in Lung Cancer
The Scientific World Journal
title Receptor Tyrosine Kinases and Inhibitors in Lung Cancer
title_full Receptor Tyrosine Kinases and Inhibitors in Lung Cancer
title_fullStr Receptor Tyrosine Kinases and Inhibitors in Lung Cancer
title_full_unstemmed Receptor Tyrosine Kinases and Inhibitors in Lung Cancer
title_short Receptor Tyrosine Kinases and Inhibitors in Lung Cancer
title_sort receptor tyrosine kinases and inhibitors in lung cancer
url http://dx.doi.org/10.1100/tsw.2004.117
work_keys_str_mv AT evanpisick receptortyrosinekinasesandinhibitorsinlungcancer
AT simhajagadeesh receptortyrosinekinasesandinhibitorsinlungcancer
AT ravisalgia receptortyrosinekinasesandinhibitorsinlungcancer